These EGFR-specific drugs can be largely divided into monoclonalantibodies (mAbs) targeting the extracellular domain (e.g., cetuximab,panitumumab, and necitumumab)9 and kinaseinhibitors such as erlotinib, gefitinib, afatinib, and osimertinib,which block the enzymatic activity of the intracellular EGFR kinasedomain.10 In many clinical centers, NSCLCsamples are routinely screened for mutations in the EGFR gene2,11 since EGFR-mutant NSCLC has been shown tobe more sensitive to EGFR-targeted kinase inhibitors.12 Here, EGFR is linked to non-small cell lung carcinoma.